Your Article Summary
See Latest ArticlesCephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
Cephalon, 07/01/09
Cephalon, Inc. announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration requesting approval of NUVIGIL Tablets for the indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. Jet lag disorder is an acute condition that occurs when a person's internal body clock becomes disrupted as a result of rapid travel across several time zones. Based on U.S. Bureau of Labor Statistics findings, an estimated 70 million American travelers experience jet lag annually.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Multaq Approved in the European Union for Patients with Atrial Fibrillation
Sanofi-aventis, 12/01/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
BioMarin, 12/01/09